Lumida
/ANIK
⌘K
Anika Therapeutics Inc

Anika Therapeutics Inc

ANIK
$21.34USD-2.02%-0.44 today

MARKET CAP

285.6M

P/E (TTM)

FWD P/E

DAY RANGE

$21 – $23

52W RANGE

$8
$23

AI Summary

Stalk
Sell NowMedium

ANIK is in a Stage 3 distribution phase, granting bearish medium-term permission. Short-term price is rejecting around the 9/21 EMAs and 50-day SMA, reflecting diminishing demand and structure failure. The preferred execution is selling into rallies near these resistance zones, aligning with the dominant downtrend while respecting potential short-term oversold bounces.

  • Q2 revenue rose 16% YoY to $32.6M, led by 17% commercial growth
  • Gross margin reached 65%, highest since 2020, driving profitability
  • OEM channel revenue down 17% YoY, highlighting pricing pressure from partners
Full analysis →
STATEMENT·Income statement
USD · GAAP
METRICFY 2021FY 2022FY 2023FY 2024FY 2025TREND
Sales, Adj.$147.8M$113.8M$120.8M$119.9M$112.8M
YoY %+13.3%-23.0%+6.1%-0.7%-5.9%
P / Sales3.5x3.8x2.7x2.0x1.2x
EV / Sales3.3x3.6x2.7x2.0x1.1x
Gross Profit, Adj.$82.9M$73.2M$82.5M$76.0M$63.8M
YoY %+20.2%-11.7%+12.7%-7.9%-16.0%
Margin %56.1%64.3%68.3%63.4%56.6%
EV / Gross Profit5.9x5.6x3.9x3.1x2.0x
EBITDA, Adj.$-2.5M$18.2M$15.1M$3.0M$-5.3M
YoY %-191.0%+839.6%-17.1%-79.9%-276.2%
Margin %-1.7%16.0%12.5%2.5%-4.7%
EV / EBITDA-199.8x22.8x21.4x78.0x-23.9x
EBIT$2.6M$3.7M$844,000$-5.1M$-11.1M
YoY %+109.2%+40.3%-77.0%-704.4%-116.6%
Margin %1.8%3.2%0.7%-4.3%-9.8%
EV / EBIT187.5x112.6x381.2x-46.2x-11.5x
Net Income$4.1M$-14.9M$-82.7M$-56.4M$-10.9M
YoY %+117.2%-459.4%-456.3%+31.8%+80.7%
Net Margin2.8%-13.1%-68.4%-47.0%-9.6%
EPS (GAAP)$0.28-$1.02-$5.64-$3.83-$0.76
YoY %+116.6%-464.3%-452.9%+32.1%+80.2%